Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks
Authors:
- C.C. OtleyCOC.C. Otley
- M D GriffinMGM D Griffin
- for the Reduction of Immunosuppression Task Force of the International Transplant Skin Cancer CollaborativeFCfor the Reduction of Immunosuppression Task Force of the International Transplant Skin Cancer Collaborative
- 1 December 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 157 (6) , 1183-1188
Abstract
Although evidence supports the efficacy of reducing immunosuppression for transplant-associated skin cancer, clinical thresholds for and risks associated with reduction are not well defined. In this study, experienced transplant physicians were surveyed regarding appropriate thresholds for consideration of reduction of immunosuppression and the likelihood of rejection and allograft compromise associated with various levels of reduction. Fifty-two transplant physicians reviewed 13 hypothetical patient scenarios with graduated morbidity and mortality risk and provided opinions on the degree of reduction of immunosuppression that was warranted and the risks associated with various degrees of reduction. Renal, liver and cardiac transplant physicians generally concurred on the level of reduction of immunosuppression warranted by various degrees of skin cancer. As morbidity and mortality from skin cancer increased, physicians were more likely to accept risk to allograft function from more aggressive reduction. Reduction of immunosuppression is considered a reasonable adjuvant strategy in recipients of solid organ transplants who have substantial morbidity and mortality risk from skin cancer. Physicians are willing to accept an increased risk of allograft compromise when confronted by severe or extensive skin cancer. Further research is needed to define the precise correlation among levels of reduction of immunosuppression, therapeutic efficacy, and concomitant risks.Keywords
This publication has 29 references indexed in Scilit:
- Reduction of immunosuppression for transplant-associated skin cancer: expert consensus surveyBritish Journal of Dermatology, 2006
- Strategies for minimizing immunosuppression in kidney transplantationTransplant International, 2005
- Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies*Clinical Transplantation, 2004
- Maintenance Versus Reduction of Immunosuppression in Renal Transplant Recipients With Aggressive Squamous Cell CarcinomaDermatologic Surgery, 2004
- Skin Cancers after Organ TransplantationNew England Journal of Medicine, 2003
- Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppressionNephrology Dialysis Transplantation, 2002
- Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?Transplant International, 2000
- Post-Transplant MalignancyDrug Safety, 2000
- Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lipJournal of the American Academy of Dermatology, 1992
- Epidermal dysplasia and cyclosporine therapy in renal transplant patients: a comparison with azathioprineBritish Journal of Dermatology, 1989